A detailed history of Huntington National Bank transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Huntington National Bank holds 1 shares of CHRS stock, worth $1. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$1
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 21, 2022

BUY
$15.81 - $18.99 $15 - $18
1 New
1 $0
Q2 2020

Jul 30, 2020

SELL
$14.43 - $19.16 $3,953 - $5,249
-274 Closed
0 $0
Q1 2020

Apr 27, 2020

SELL
$11.67 - $22.53 $9,511 - $18,361
-815 Reduced 74.84%
274 $4,000
Q4 2019

Jan 17, 2020

BUY
$16.33 - $21.37 $4,000 - $5,235
245 Added 29.03%
1,089 $20,000
Q3 2019

Nov 01, 2019

BUY
$16.3 - $23.37 $13,757 - $19,724
844 New
844 $17,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $134M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.